Health Professional Radio - Podcast

Dr. Josefa Briceno, M.D., Medical Head for the DNA Damage Response Franchise in US Medical Affairs at AstraZeneca discusses the recent FDA approval of LYNPARZA® (olaparib) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Approval was based on results from the Phase III PROfound trial, which were published in the "New England Journal of Medicine".